TAVR may be a safe, effective treatment strategy for patients with moderate aortic stenosis and at least one other warning sign of heart disease. That was the key takeaway from a highly anticipated late-breaking study presented by Philippe Généreux, MD, at TCT 2026 in San Diego. 

CMS just finalized major updates to its TAVR coverage policies. Could even more change be on the horizon? 

The ACC, SCAI and STS have shared early support for expanding Medicare coverage to include TAVR in patients with native AR. The groups emphasized that CED requirements and multidisciplinary heart team meetings are necessary to ensure patients receive the best possible care going forward.

Self-expanding valves, a history of stroke, renal dysfunction and nontransfemoral access were all linked to an increased risk of in-hospital stroke after TAVR. “Despite advances in valve design and technique, the overall stroke rate has plateaued,” researchers wrote.

The upfront costs may be higher, but new data presented at TCT 2026 showed that treating asymptomatic patients with TAVR instead of clinical surveillance was a highly cost-effective intervention. 

Surgical bailout during TAVR is growing increasingly rare as time goes on. Does that mean it is time to rethink certain coverage policies? A new study and two separate editorials examined this topic in great detail.

The recent PRO-TAVI trial showed that care teams can safely perform PCI at a later date when patients undergoing TAVR present with concomitant coronary artery disease. According to this latest analysis, however, there may still be certain patients who benefit from undergoing PCI prior to TAVR.

Researchers tracked years of real-world data, noting that the mortality rates for TAVR and SAVR were comparable once patients were discharged.

TAVR Assist+ was built to capture patient measurements and perform other straightforward tasks. This gives cardiologists more time to make critical treatment decisions.

This Class II recall was initiated due to a risk of clinicians encountering issues when deploying the Trilogy Transcatheter Heart Valve System.